News & Events

• September 1, 2022
  

  C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases

  C-Path today announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).

• August 25, 2022
  

  Oak Hill Bio Joins C-Path’s International Neonatal Consortium

  C-Path today announced that Oak Hill Bio (Oak Hill), a clinical-stage neonatology and rare disease therapeutics company, has become a member of its International Neonatal Consortium (INC).

• June 1, 2022
  

  C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database

  C-Path has received fully anonymized electronic patient record (EPR) data from the National Neonatal Research Database (NNRD). This is part of efforts to better understand and find treatments for a chronic lung disease which frequently affects premature infants. This initiative, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). It is the first time C-Path has received EPR data from the United Kingdom and includes data from a network of nearly 200 hospitals in England.

• March 10, 2022
  

  C-Path and Tufts Medical Center Collaborate on EHR Data Transfer

  The endeavor represents a major milestone for C-Path   TUCSON, Ariz., March 10, 2022 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a collaboration to transfer electronic healthcare records (EHR) data to C-Path as part of the real-world data (RWD) effort to generate actionable real-world evidence (RWE) for neonatal drug development. This...
• December 1, 2021
  

  C-Path and NICHD to Share Real-world Data to Advance Neonatal Drug Development

  International Neonatal Consortium (INC) today announced a seminal data-sharing collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health, as a part of a U.S. Food and Drug Administration (FDA) sponsored project to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD).